共 48 条
- [41] Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trialJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (05) : 1282 - 1293Paller, Amy S.Siegfried, Elaine C.Thaci, DiamantWollenberg, AndreasCork, Michael J.Arkwright, Peter D.Gooderham, MelindaBeck, Lisa A.Boguniewicz, MarkSher, LawrenceWeisman, JamieO'Malley, John T.Patel, NaimishHardin, MeganGraham, Neil M. H.Ruddy, MarcellaSun, XianDavis, John D.Kamal, Mohamed A.Khokhar, Faisal A.Weinreich, David M.Yancopoulos, George D.Beazley, BethanyBansal, AshishShumel, Brad
- [42] Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension StudyAMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2024, 25 (04) : 655 - 668Paller, Amy S.Siegfried, Elaine C.Simpson, Eric L.Cork, Michael J.Sidbury, RobertChen, Iris H.Khokhar, Faisal A.Xiao, JingDubost-Brama, ArianeBansal, Ashish
- [43] A randomized phase I trial of intranasal SARS-CoV-2 vaccine dNS1-RBD in children aged 3-17 yearsNPJ VACCINES, 2025, 10 (01)Chu, KaiQuan, JialiLiu, XiaohuiChen, QiZang, XiaJiang, HanminLiu, DonglinChu, XiafeiZhuang, ChunlanHan, JinleYe, XiangzhongPan, HongxingHuang, ShoujieWu, TingZhang, JunXia, Ningshao
- [44] Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, doubleblinded, placebo-controlled phase 3 trial (vol 83, pg 1282, 2020)JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 84 (01) : 230 - 230Paller, A. S.Siegfried, E. C.Thaci, D.
- [45] Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINETrial VX21-121-105): an analysis from a single-arm, phase 3 trialLANCET RESPIRATORY MEDICINE, 2025, 13 (03): : 244 - 255Hoppe, Jordana E.Kasi, Ajay S.Pittman, Jessica E.Jensen, ReneeThia, Lena P.Robinson, PhilipTirakitsoontorn, PornchaiRamsey, BonnieMall, Marcus A.Taylor-Cousar, Jennifer L.Mckone, Edward F.Tullis, ElizabethSalinas, Danieli B.Zhu, JiaqiangChen, Yih-ChiehRodriguez-Romero, VioletaSosnay, Patrick R.Davies, Gwyneth
- [46] Clinically Meaningful Responses to Dupilumab Among Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis who did Not Achieve Clear or Almost Clear Skin According to the Investigator's Global Assessment: A Post Hoc Analysis of a Phase 3 TrialACTA DERMATO-VENEREOLOGICA, 2024, 104Cork, Michael J.Lockshin, BenjaminPinter, AndreasChen, ZhenShumel, BradPrescilla, Randy
- [47] Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17years in China: a randomised, double-blind, placebo- controlled, phase 1trial and an open-label, non-randomised, non-inferiority, phase 2 trialLANCET CHILD & ADOLESCENT HEALTH, 2023, 7 (04): : 269 - 279Gao, LidongLi, YanHe, PengChen, ZhenYang, HuaiyuLi, FangjunZhang, SiyuanWang, DanniWang, GuangyanYang, ShilongGong, LihuiDing, FanLing, MengyuWang, XiluCi, LeileiDai, LianpanGao, George FuHuang, TaoHu, ZhongyuYing, ZhifangSun, JiufengZuo, Xiaohu
- [48] Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trialLANCET, 2024, 403 (10432): : 1164 - 1175Ochoge, MagnusFuta, Ahmed ChernoUmesi, AmaAffleck, LucyKotei, LarryDaffeh, BaboucarrSaidy-Jah, EbrimaNjie, AnnaOyadiran, OluwafemiEdem, BasseyJallow, MusaJallow, EdrissaDonkor, Simon A.Tritama, ErmanAbid, TalhaJones, Kathryn A., VMainou, Bernardo A.Konz, JohnFix, AlanGast, ChrisClarke, Ed